Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding trial
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Ponatinib (Primary) ; Antineoplastics
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms MATCHPOINT
- 06 Nov 2019 Results (n=17) presented in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 09 Oct 2018 Planned End Date changed from 15 Sep 2017 to 26 Apr 2021.
- 09 Oct 2018 Status changed from completed to active, no longer recruiting.